Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Darya-Varia Laboratoria TbkISX:DVLA -0.32%70 5-Year Yield-on-Cost % is 6.59 as of Aug. 14, 2026, which is 30% above its 10-year median of 5.07. GuruFocus rates ISX:DVLA with a GF Score™ of 70/100 and a GF Value™ of Rp1,861.90 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 511 Drug Manufacturers companies, PT Darya-Varia Laboratoria Tbk ranks better than 80.63% on this metric.
The historical rank and industry rank for PT Darya-Varia Laboratoria Tbk's 5-Year Yield-on-Cost % or its related term are showing as below:
ISX:DVLA'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.29 Med: 5.07 Max: 8.67
Current: 6.59
During the past 13 years, PT Darya-Varia Laboratoria Tbk's highest Yield on Cost was 8.67. The lowest was 1.29. And the median was 5.07.
ISX:DVLA's 5-Year Yield-on-Cost % is ranked better than 80.63% of 511
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs ISX:DVLA: 6.59
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
PT Darya-Varia Laboratoria Tbk 5-Year Yield-on-Cost % Related Terms
ISX:DVLA vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Darya-Varia Laboratoria Tbk's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Darya-Varia Laboratoria Tbk 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Darya-Varia Laboratoria Tbk's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where PT Darya-Varia Laboratoria Tbk's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
PT Darya-Varia Laboratoria Tbk (ISX:DVLA) has a 5-Year Yield-on-Cost % of 6.59 as of Aug. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. This is 30% above median its historical median of 5.07. Over the past decade, PT Darya-Varia Laboratoria Tbk's 5-Year Yield-on-Cost % has ranged from 1.29 to 8.67. According to the industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #99 out of 511 companies in the Drug Manufacturers industry, placing it in the top 19.4%.
Is PT Darya-Varia Laboratoria Tbk's 5-Year Yield-on-Cost % too high?
PT Darya-Varia Laboratoria Tbk's current 5-Year Yield-on-Cost % of 6.59 is 30% above median its 10-year median of 5.07. Over the past 10 years, this metric has ranged from a low of 1.29 to a high of 8.67. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.30. PT Darya-Varia Laboratoria Tbk's value of 6.59 is 186.5% above this industry median. Based on the distribution chart, PT Darya-Varia Laboratoria Tbk ranks #99 out of 511 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PT Darya-Varia Laboratoria Tbk has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Darya-Varia Laboratoria Tbk's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #99 out of 511 companies for 5-Year Yield-on-Cost %. This places PT Darya-Varia Laboratoria Tbk in the top 19% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.30. PT Darya-Varia Laboratoria Tbk's value of 6.59 is 186.5% above this benchmark. Historically, PT Darya-Varia Laboratoria Tbk's own 5-Year Yield-on-Cost % has ranged from 1.29 to 8.67 over the past decade. While the company's 10-year median is 5.07 vs. the industry median of 2.30, PT Darya-Varia Laboratoria Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.30, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Darya-Varia Laboratoria Tbk's current 5-Year Yield-on-Cost % of 6.59 is 186.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Darya-Varia Laboratoria Tbk's current 5-Year Yield-on-Cost % is 6.59, which is 30% above median its own 10-year median of 5.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Darya-Varia Laboratoria Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk (ISX:DVLA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp1,861.90, compared to a current price of Rp1,580.00 — trading 15.1% below its estimated fair value. The current 5-Year Yield-on-Cost % is 6.59, which is 30% above median its 10-year median of 5.07 and 186.5% above the Drug Manufacturers industry median of 2.30. PT Darya-Varia Laboratoria Tbk's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For PT Darya-Varia Laboratoria Tbk (ISX:DVLA), the current 5-Year Yield-on-Cost % is 6.59 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Darya-Varia Laboratoria Tbk (ISX:DVLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk stock appears to be undervalued.
The current stock price of Rp1,580.00 is trading 15.1% below its estimated GF Value™ of Rp1,861.90.
GuruFocus considers PT Darya-Varia Laboratoria Tbk to be Modestly Undervalued.
Key valuation signals for ISX:DVLA:
5-Year Yield-on-Cost %: 6.59 (30% above median its 10-year median of 5.07)
GF Value™: Rp1,861.90 vs. price of Rp1,580.00 (15.1% below fair value)
Industry Position: 186.5% above the Drug Manufacturers median (#99 of 511)
No single metric tells the full story. See the ISX:DVLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, and equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics, wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory testing services, periodic inspection services, and many more activities. Its business segments include: prescription drugs; consumer health products, which derives key revenue; export and toll manufacturing services; and services.
70GF Score
Get the complete analysis for ISX:DVLA
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:DVLA has been successfully added to your 
